These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12514786)

  • 21. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene.
    Sekido Y; Takahashi T; Ueda R; Takahashi M; Suzuki H; Nishida K; Tsukamoto T; Hida T; Shimokata K; Zsebo KM
    Cancer Res; 1993 Apr; 53(7):1709-14. PubMed ID: 7680956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma.
    Edwards PC; Bhuiya T; Kelsch RD
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 May; 95(5):586-93. PubMed ID: 12738950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach.
    Bar-Sela G; Kuten A; Ben-Eliezer S; Gov-Ari E; Ben-Izhak O
    Mod Pathol; 2003 Oct; 16(10):1035-40. PubMed ID: 14559987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A new strategy for treating small cell lung cancer].
    Ueda R; Takashi T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Dec; 34 Suppl():111-4. PubMed ID: 9216197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
    Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
    Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
    Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
    Kara IO; Gonlusen G; Sahin B; Ergin M; Erdogan S
    Saudi Med J; 2005 Aug; 26(8):1190-6. PubMed ID: 16127511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
    J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
    Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
    Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas.
    Jiang SX; Sato Y; Kuwao S; Kameya T
    J Pathol; 1995 Oct; 177(2):135-8. PubMed ID: 7490679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray.
    Langner C; Lemmerer M; Kornprat P
    Eur J Surg Oncol; 2004 Oct; 30(8):847-50. PubMed ID: 15336730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
    Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma.
    Ishikubo T; Akagi K; Kurosumi M; Yamaguchi K; Fujimoto T; Sakamoto H; Tanaka Y; Ochiai A
    Jpn J Clin Oncol; 2006 Aug; 36(8):494-8. PubMed ID: 16844734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.